Physician profile
Jonathan S Wolf
NPI 1649281486
$1,417.46
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $382.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $232.18 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $185.08 | 2019 | |
| Opko Pharmaceuticals, LLC | $142.15 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $112.41 | 2019-2020 | |
| Genzyme Corporation | $111.99 | 2019 | |
| Amgen INC. | $109.67 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $74.47 | 2019 | |
| Amarin Pharma, INC. | $73.69 | 2019-2020 | |
| Travere Therapeutics, INC. | $57.98 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $54.20 | 2019-2020 | |
| Novo Nordisk INC | $51.62 | 2019-2020 | |
| Vifor Pharma, INC. | $51.40 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $43.93 | 2019 | |
| Daiichi Sankyo INC. | $32.39 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.26 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.24 | 2019 | |
| Akebia Therapeutics INC | $16.20 | 2019 | |
| Glaxosmithkline, LLC. | $15.23 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $14.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.